Nanobiotix (Euronext: NANO / ISIN: FR0011341205) late clinical-stage company pioneering novel nanomedicines to cancer treatment. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy (RT) energy with a view to providing a new, more efficient treatment for cancer patients.

NBTXR3 the lead product is compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors.

NBTXR3 is being evaluated in Phase II/III (soft tissue sarcoma) and Phase I/II (head and neck cancers, prostate cancer, and liver cancers). Additionally, head and neck cancer and rectal cancer phase I/II trials are underway in Asia Pacific region and lead by Nanobiotix’s partner, PharmaEngine.

The Company is running research programs in immuno-oncology with NBTXR3 that could have the potential to bring a new dimension to cancer immunotherapies.

FDA granted in December 2017 an IND for a clinical trial with NBTXR3 activated by RT in combination with anti-PD1 antibody in lung, and head and neck cancer patients in the U.S.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company’s Headquarters are based in Paris, France, the U.S. affiliate is in Cambridge, MA.